Prevalence and Predictive Value of Sarcopenia in Surgically Treated Cholangiocarcinoma: a Comprehensive Review and Meta-analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Apr 4

PMID 38571501

Authors

Jie He

Yuanyuan Huang

Na Huang

Jiaqing Jiang

Affiliations

Soon will be listed here.

Abstract

Background: Sarcopenia, marked by a reduction in skeletal muscle mass and function, is a condition that can manifest in elderly patients with cancer and has been recognized as a possible adverse factor affecting the survival of individuals diagnosed with malignant tumors. This systematic review and meta-analysis aimed to examine the prevalence of sarcopenia in individuals with cholangiocarcinoma while concurrently investigating the potential correlations between the presence of sarcopenia and various critical factors, including survival outcomes and postoperative complications.

Methods: A comprehensive search was conducted across multiple databases, including EMBASE, PubMed, Web of Science, Cochrane Library, and CNKI, employing keywords such as sarcopenia, cholangiocarcinoma, and prognosis. This research explored the prognostic value of sarcopenia on the survival of cholangiocarcinoma. The findings of this meta-analysis were presented using forest plots and a summarized effects model. The Newcastle-Ottawa Scale (NOS) was employed to evaluate the quality of the studies included in the analysis.

Results: A total of 33 articles from five databases were in in the quantitative analysis. A comprehensive meta-analysis revealed that the overall prevalence of sarcopenia among individuals diagnosed with cholangiocarcinoma was43%. Moreover, the analysis revealed a significant and noteworthy correlation between sarcopenia and key clinical parameters such as overall survival (OS), Recurrence-Free Survival (RFS), and Disease-Free Survival (DFS) in patients with cholangiocarcinoma. Subgroup analysis revealed that, when categorized by various ethnicities, diagnostic techniques, and tumor locations, sarcopenia consistently retained its status as a negative predictive factor. Furthermore, sarcopenia has emerged as a risk factor for postoperative complications. All included studies had an NOS score greater than 5, indicating a high quality of evidence.

Conclusion: The results suggest that sarcopenia is significantly related to survival outcomes and postoperative complications in cholangiocarcinoma. Appropriate diagnosis and treatment of sarcopenia should be implemented to improve the prognosis of individuals with cholangiocarcinoma.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023479866, identifier CRD42023479866.

Citing Articles

Prognostic Significance of Sarcopenia in Patients Undergoing Surgery for Perihilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis.

Efstathiou A, Suarez Benitez P, Hajibandeh S, Hajibandeh S, Satyadas T Cancers (Basel). 2025; 17(5).

PMID: 40075684 PMC: 11899633. DOI: 10.3390/cancers17050837.

References

Yu H, Wang M, Wang Y, Yang J, Deng L, Bao W . The prognostic value of sarcopenia combined with preoperative fibrinogen-albumin ratio in patients with intrahepatic cholangiocarcinoma after surgery: A multicenter, prospective study. Cancer Med. 2021; 10(14):4768-4780. PMC: 8290250. DOI: 10.1002/cam4.4035. View

Tan B, Brammer K, Randhawa N, Welch N, Parsons S, James E . Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2014; 41(3):333-8. DOI: 10.1016/j.ejso.2014.11.040. View

Forouzannezhad P, Maes D, Hippe D, Thammasorn P, Iranzad R, Han J . Multitask Learning Radiomics on Longitudinal Imaging to Predict Survival Outcomes following Risk-Adaptive Chemoradiation for Non-Small Cell Lung Cancer. Cancers (Basel). 2022; 14(5). PMC: 8909466. DOI: 10.3390/cancers14051228. View

Su H, Ruan J, Chen T, Lin E, Shi L . CT-assessed sarcopenia is a predictive factor for both long-term and short-term outcomes in gastrointestinal oncology patients: a systematic review and meta-analysis. Cancer Imaging. 2019; 19(1):82. PMC: 6892174. DOI: 10.1186/s40644-019-0270-0. View

Umetsu S, Wakiya T, Ishido K, Kudo D, Kimura N, Miura T . Effect of sarcopenia on the outcomes after pancreaticoduodenectomy for distal cholangiocarcinoma. ANZ J Surg. 2018; 88(9):E654-E658. DOI: 10.1111/ans.14304. View

Liu J, Liu Y, Zhang Y, Zheng J, Wang S, Cao G . Circular RNA hsa_circ_0004543 Aggravates Cervical Cancer Development by Sponging MicroRNA hsa-miR-217 to Upregulate Hypoxia-Inducible Factor. J Oncol. 2022; 2022:4031403. PMC: 8926462. DOI: 10.1155/2022/4031403. View

Kim S, Lee H, Bang S, Han D, Hwang H, Choi G . Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma. Cancers (Basel). 2021; 13(8). PMC: 8069292. DOI: 10.3390/cancers13081828. View

Zhao Z, Bo Z, Ye N, Dong Y, Xu Y, Wang B . Impact of sarcopenia on postoperative outcomes after hepatectomy in older patients with intrahepatic cholangiocarcinoma: A multicentre cohort study. Liver Int. 2023; 44(1):155-168. DOI: 10.1111/liv.15757. View

Taniai T, Haruki K, Yanagaki M, Igarashi Y, Furukawa K, Onda S . Osteosarcopenia predicts poor prognosis for patients with intrahepatic cholangiocarcinoma after hepatic resection. Surg Today. 2022; 53(1):82-89. DOI: 10.1007/s00595-022-02550-3. View

10.

Yasuta S, Sugimoto M, Kudo M, Kobayashi S, Takahashi S, Konishi M . Early postoperative decrease of skeletal muscle mass predicts recurrence and poor survival after surgical resection for perihilar cholangiocarcinoma. BMC Cancer. 2022; 22(1):1358. PMC: 9795591. DOI: 10.1186/s12885-022-10453-2. View

11.

Srikanthan P, Hevener A, Karlamangla A . Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PLoS One. 2012; 5(5):e10805. PMC: 3279294. DOI: 10.1371/journal.pone.0010805. View

12.

Li H, Dai J, Lan T, Liu H, Wang J, Cai B . Combination of albumin-globulin score and skeletal muscle index predicts long-term outcomes of intrahepatic cholangiocarcinoma patients after curative resection. Clin Nutr. 2021; 40(6):3891-3900. DOI: 10.1016/j.clnu.2021.04.038. View

13.

Ishihara S, Horiguchi A, Miyakawa S, Endo I, Miyazaki M, Takada T . Biliary tract cancer registry in Japan from 2008 to 2013. J Hepatobiliary Pancreat Sci. 2015; 23(3):149-57. DOI: 10.1002/jhbp.314. View

14.

Yoon S, Choi M, Song M, Lee J, Lee I, Lee M . Impact of preoperative body compositions on survival following resection of biliary tract cancer. J Cachexia Sarcopenia Muscle. 2019; 10(4):794-802. PMC: 6711415. DOI: 10.1002/jcsm.12431. View

15.

Mir O, Coriat R, Dhooge M, Perkins G, Boudou-Rouquette P, Brezault C . Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2. Anticancer Drugs. 2012; 23(7):739-44. DOI: 10.1097/CAD.0b013e3283556b9b. View

16.

Tadesse A, Anto T, Birhanu M, Agedew E, Yimer B, Abejie A . Prevalence of undernutrition and its associated factors among older adults using Mini Nutritional Assessment tool in Womberma district, West Gojjam Zone, Amhara Region, North West Ethiopia, 2020. PLoS One. 2023; 18(2):e0274557. PMC: 9955662. DOI: 10.1371/journal.pone.0274557. View

17.

Wingard J, Majhail N, Brazauskas R, Wang Z, Sobocinski K, Jacobsohn D . Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011; 29(16):2230-9. PMC: 3107742. DOI: 10.1200/JCO.2010.33.7212. View

18.

Hayashi K, Abe Y, Kitago M, Yagi H, Hasegawa Y, Hori S . Prognostic impact of preoperative skeletal muscle change from diagnosis to surgery in patients with perihilar cholangiocarcinoma. Ann Gastroenterol Surg. 2023; 7(3):523-532. PMC: 10154860. DOI: 10.1002/ags3.12644. View

19.

Castillo-Martinez L, Castro-Eguiluz D, Copca-Mendoza E, Perez-Camargo D, Reyes-Torres C, Avila E . Nutritional Assessment Tools for the Identification of Malnutrition and Nutritional Risk Associated with Cancer Treatment. Rev Invest Clin. 2018; 70(3):121-125. DOI: 10.24875/RIC.18002524. View

20.

Sookprasert A, Wirasorn K, Chindaprasirt J, Watcharenwong P, Sanlung T, Putraveephong S . Systemic Treatment for Cholangiocarcinoma. Recent Results Cancer Res. 2023; 219:223-244. DOI: 10.1007/978-3-031-35166-2_8. View